STAA STAAR Surgical Co: צמיחה צפויה ברווח למניה לשנה הבאה

STAAR Surgical Company (STAA) minimizes reliance on third-party suppliers by independently synthesizing Collamer biomaterial. The net income per share growth target for the coming year in the GURU.Markets chart data sequence confirms this, where 69.00 shows the current value of the metric. STAAR Surgical Company (STAA) is scaling its expansion through educational centers for surgeons, maintaining leadership in the phakic lens segment thanks to strong patent protection.
פילוחים אנליטיים של חברת STAAR Surgical Company

Casting automation and high capacity utilization at STAAR Surgical Company (STAA) for lens production establish a foundation for scaling operational efficiency. The consensus EPS growth forecast for the coming year measures the expected earnings per share dynamics, allowing GURU.Markets investors to filter out market noise and assess the fundamental value potential of the business via this 12-month expected EPS growth chart.